Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.

BACKGROUND AND OBJECTIVES A male infant with a family history of thrombotic microangiopathy developed atypical hemolytic uremic syndrome (aHUS). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Case report. RESULTS Genetic analysis demonstrated a heterozygous mutation (S1191L) of CFH, the gene coding complement factor H (CFH). The child suffered many episodes of HUS, each treated with plasma exchange. In time, despite initiation of a prophylactic regimen of plasma exchange, his renal function declined significantly. At the age of 4 yr he received a (split liver) combined liver-kidney transplant (LKT) with preoperative plasma exchange and enoxaparin anticoagulation. Initial function of both grafts was excellent and is maintained for nearly 2 yr. CONCLUSIONS This report adds to the small but growing number of individuals in whom LKT has provided a favorable outcome for aHUS associated with CFH mutation, expands the technique of using a split liver graft, and describes the unique histologic features of subclinical liver disease in HUS.

[1]  G. Remuzzi,et al.  Successful Liver‐Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  P. de Lagausie,et al.  Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. , 2007, European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie.

[3]  G. Remuzzi,et al.  Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. , 2007, Molecular immunology.

[4]  John D Lambris,et al.  New approaches to the treatment of dense deposit disease. , 2007, Journal of the American Society of Nephrology : JASN.

[5]  L. Heuvel,et al.  A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome , 2007, Pediatric Nephrology.

[6]  R. Salomon,et al.  A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. , 2007, Molecular immunology.

[7]  Toru Watanabe.  Thrombotic microangiopathy and intravenous immunoglobulin therapy , 2007, Pediatric nephrology (Berlin, West).

[8]  S. Ito,et al.  Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology , 2007, Pediatric Nephrology.

[9]  G. Deschênes,et al.  Secondary failure of plasma therapy in factor H deficiency , 2006, Pediatric Nephrology.

[10]  G. Remuzzi,et al.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.

[11]  G. Remuzzi,et al.  Favorable Long‐Term Outcome after Liver‐Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  D. Kavanagh,et al.  Membrane cofactor protein and factor I: mutations and transplantation. , 2006, Seminars in thrombosis and hemostasis.

[13]  M. Jackson,et al.  De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome , 2006, Human mutation.

[14]  R. Stefanov,et al.  Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[15]  N. Perico,et al.  Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  P. Zipfel,et al.  Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  W. Fridman,et al.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome , 2004, Journal of Medical Genetics.

[18]  M. Bellamy,et al.  Complement membrane attack complex and hemodynamic changes during human orthotopic liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  G. Remuzzi,et al.  Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. , 2003, Human molecular genetics.

[20]  P. Niaudet,et al.  The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children , 2003, Pediatric Nephrology.

[21]  D. Lenk,et al.  Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries , 2003, Journal of medical genetics.

[22]  J. Goodship,et al.  Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality , 2003, Pediatric Nephrology.

[23]  G. Remuzzi,et al.  Combined kidney and liver transplantation for familial haemolytic uraemic syndrome , 2002, The Lancet.

[24]  S. Frøland,et al.  Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment , 2001, Circulation.

[25]  T. Nagasawa,et al.  Inhibition of complement‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low‐molecular weight heparin , 2000, British journal of haematology.

[26]  J. Mahan,et al.  Infarction of the choledochus, liver, gallbladder, and pancreas: a unique complication of the hemolytic uremic syndrome. , 2000, Journal of pediatric surgery.

[27]  J. Goodship,et al.  Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  G. Remuzzi,et al.  Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 1999, Journal of the American Society of Nephrology : JASN.

[29]  M. Kazatchkine,et al.  Human complement factor H deficiency associated with hemolytic uremic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[30]  Fontana,et al.  High‐Dose Intravenous Immunoglobulin Treatment Activates Complement In Vivo , 1998, Scandinavian journal of immunology.

[31]  S. Semhoun-Ducloux,et al.  Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis. , 1998, Transplantation.

[32]  B. Burke,et al.  Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  C. Degott,et al.  Complement activation after ischemia-reperfusion in human liver allografts: incidence and pathophysiological relevance. , 1997, Gastroenterology.

[34]  R. Siegler.  Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. , 1994, The Journal of pediatrics.

[35]  J. Atkinson,et al.  Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. , 1993, Clinical and experimental immunology.

[36]  M. Heyman,et al.  Thrombotic thrombocytopenic purpura treated with high-dose intravenous gamma globulin. , 1990, Southern medical journal.

[37]  K. Farrington,et al.  Cholestatic jaundice in the haemolytic-uraemic syndrome: a case report. , 1985, Gut.

[38]  G. Schwartz,et al.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine , 2004 .

[39]  G. Schwartz,et al.  A Simple Estimate of Glomerular Filtration Rate in Children Derived From Body Length and Plasma Creatinine , 1976, Pediatrics.

[40]  S. Cutillo.  [Hemolytic-uremic syndrome]. , 1973, La Pediatria.

[41]  G. Remuzzi,et al.  Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. , 2007, Molecular immunology.

[42]  C. Porta,et al.  Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP. , 1995, Haematologica.

[43]  M. Frank,et al.  High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. , 1991, Blood.